Literature DB >> 29449679

TERT promoter mutation in adult granulosa cell tumor of the ovary.

Jessica A Pilsworth1,2, Dawn R Cochrane2, Zhouchunyang Xia2,3, Geraldine Aubert4, Anniina E M Färkkilä5,6, Hugo M Horlings2,3, Satoshi Yanagida7, Winnie Yang2, Jamie L P Lim2, Yi Kan Wang2, Ali Bashashati2, Jacqueline Keul8, Adele Wong9, Kevin Norris10, Sara Y Brucker8, Florin-Andrei Taran8, Bernhard Krämer8, Annette Staebler11, Hannah van Meurs12, Esther Oliva9, Sohrab P Shah2,13, Stefan Kommoss8, Friedrich Kommoss14, C Blake Gilks3, Duncan M Baird10, David G Huntsman15,16.   

Abstract

The telomerase reverse transcriptase (TERT) gene is highly expressed in stem cells and silenced upon differentiation. Cancer cells can attain immortality by activating TERT to maintain telomere length and telomerase activity, which is a crucial step of tumorigenesis. Two somatic mutations in the TERT promoter (C228T; C250T) have been identified as gain-of-function mutations that promote transcriptional activation of TERT in multiple cancers, such as melanoma and glioblastoma. A recent study investigating TERT promoter mutations in ovarian carcinomas found C228T and C250T mutations in 15.9% of clear cell carcinomas. However, it is unknown whether these mutations are frequent in other ovarian cancer subtypes, in particular, sex cord-stromal tumors including adult granulosa cell tumors. We performed whole-genome sequencing on ten adult granulosa cell tumors with matched normal blood and identified a TERT C228T promoter mutation in 50% of tumors. We found that adult granulosa cell tumors with mutated TERT promoter have increased expression of TERT mRNA and exhibited significantly longer telomeres compared to those with wild-type TERT promoter. Extension cohort analysis using allelic discrimination revealed the TERT C228T mutation in 51 of 229 primary adult granulosa cell tumors (22%), 24 of 58 recurrent adult granulosa cell tumors (41%), and 1 of 22 other sex cord-stromal tumors (5%). There was a significant difference in overall survival between patients with TERT C228T promoter mutation in the primary tumors and those without it (p = 0.00253, log-rank test). In seven adult granulosa cell tumors, we found the TERT C228T mutation present in recurrent tumors and absent in the corresponding primary tumor. Our data suggest that TERT C228T promoter mutations may have an important role in progression of adult granulosa cell tumors.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29449679     DOI: 10.1038/s41379-018-0007-9

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  13 in total

1.  Discovery of New Fusion Transcripts in a Cohort of Pediatric Solid Cancers at Relapse and Relevance for Personalized Medicine.

Authors:  Célia Dupain; Anne C Harttrampf; Yannick Boursin; Manuel Lebeurrier; Windy Rondof; Guillaume Robert-Siegwald; Pierre Khoueiry; Birgit Geoerger; Liliane Massaad-Massade
Journal:  Mol Ther       Date:  2018-11-02       Impact factor: 11.454

2.  Adult Granulosa Cell Tumor With Sarcomatous Transformation: A Case Study With Emphasis on Molecular Alterations.

Authors:  Wissam Dahoud; Jesse Handler; Vamsi Parimi; Christian F Meyer; Stephanie L Wethington; James R Eshleman; Russell Vang; Brigitte M Ronnett; Deyin Xing
Journal:  Int J Gynecol Pathol       Date:  2021-12-03       Impact factor: 3.326

3.  A Pan-Cancer Study of Somatic TERT Promoter Mutations and Amplification in 30,773 Tumors Profiled by Clinical Genomic Sequencing.

Authors:  Sounak Gupta; Chad M Vanderbilt; Yun-Te Lin; Jamal K Benhamida; Achim A Jungbluth; Satshil Rana; Amir Momeni-Boroujeni; Jason C Chang; Tiffany Mcfarlane; Paulo Salazar; Kerry Mullaney; Sumit Middha; Ahmet Zehir; Anuradha Gopalan; Tejus A Bale; Ian Ganly; Maria E Arcila; Ryma Benayed; Michael F Berger; Marc Ladanyi; Snjezana Dogan
Journal:  J Mol Diagn       Date:  2020-12-05       Impact factor: 5.568

4.  KMT2D/MLL2 inactivation is associated with recurrence in adult-type granulosa cell tumors of the ovary.

Authors:  R Tyler Hillman; Joseph Celestino; Christopher Terranova; Hannah C Beird; Curtis Gumbs; Latasha Little; Tri Nguyen; Rebecca Thornton; Samantha Tippen; Jianhua Zhang; Karen H Lu; David M Gershenson; Kunal Rai; Russell R Broaddus; P Andrew Futreal
Journal:  Nat Commun       Date:  2018-06-27       Impact factor: 14.919

5.  Role of adjuvant chemotherapy in the management of stage IC ovarian granulosa cell tumors.

Authors:  Dimitrios Nasioudis; Emily M Ko; Ashley F Haggerty; Robert L Giuntoli; Robert A Burger; Mark A Morgan; Nawar A Latif
Journal:  Gynecol Oncol Rep       Date:  2019-04-17

Review 6.  Presence and role of stem cells in ovarian cancer.

Authors:  Natasa Kenda Suster; Irma Virant-Klun
Journal:  World J Stem Cells       Date:  2019-07-26       Impact factor: 5.326

7.  Prevalence of predictive biomarkers in a large cohort of molecularly defined adult-type ovarian granulosa cell tumors.

Authors:  R Tyler Hillman; Douglas I Lin; Barrett Lawson; David M Gershenson
Journal:  Gynecol Oncol       Date:  2021-07-06       Impact factor: 5.304

Review 8.  Molecular Pathways and Targeted Therapies for Malignant Ovarian Germ Cell Tumors and Sex Cord-Stromal Tumors: A Contemporary Review.

Authors:  Asaf Maoz; Koji Matsuo; Marcia A Ciccone; Shinya Matsuzaki; Maximilian Klar; Lynda D Roman; Anil K Sood; David M Gershenson
Journal:  Cancers (Basel)       Date:  2020-05-29       Impact factor: 6.639

9.  Genomic profiling of primary and recurrent adult granulosa cell tumors of the ovary.

Authors:  Arnaud Da Cruz Paula; Edaise M da Silva; Sheila E Segura; Fresia Pareja; Rui Bi; Pier Selenica; Sarah H Kim; Lorenzo Ferrando; Mahsa Vahdatinia; Robert A Soslow; August Vidal; Sonia Gatius; Christopher G Przybycin; Nadeem R Abu-Rustum; Xavier Matias-Guiu; Brian P Rubin; Jorge S Reis-Filho; Deborah F DeLair; Britta Weigelt
Journal:  Mod Pathol       Date:  2020-03-12       Impact factor: 7.842

10.  Circulating miRNA Profiling in Plasma Samples of Ovarian Cancer Patients.

Authors:  András Penyige; Éva Márton; Beáta Soltész; Melinda Szilágyi-Bónizs; Róbert Póka; János Lukács; Lajos Széles; Bálint Nagy
Journal:  Int J Mol Sci       Date:  2019-09-13       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.